Development of a simple predictive model for decreased skeletal muscle mass in patients with compensated chronic liver disease

2017 ◽  
Vol 47 (12) ◽  
pp. 1223-1234 ◽  
Author(s):  
Hiroki Nishikawa ◽  
Hirayuki Enomoto ◽  
Akio Ishii ◽  
Yoshinori Iwata ◽  
Yuho Miyamoto ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Predictive Model ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Chronic Liver

Calculated body muscle mass as a useful screening marker for low skeletal muscle mass and sarcopenia in chronic liver disease

2020 ◽  
Vol 50 (6) ◽  
pp. 704-714
Author(s):  
Tatsuki Ichikawa ◽  
Hisamitsu Miyaaki ◽  
Satoshi Miuma ◽  
Yasuhide Motoyoshi ◽  
Mio Yamashima ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Chronic Liver ◽  
Body Muscle ◽  
Screening Marker

Loss of skeletal muscle mass in patients with chronic liver disease is related to decrease in bone mineral density and exercise tolerance

2017 ◽  
Vol 48 (5) ◽  
pp. 345-354 ◽  
Author(s):  
Fumikazu Hayashi ◽  
Masaki Kaibori ◽  
Tatsuma Sakaguchi ◽  
Kosuke Matsui ◽  
Morihiko Ishizaki ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Skeletal Muscle ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Muscle Mass ◽  
Bone Mineral ◽  
Exercise Tolerance ◽  
Skeletal Muscle Mass ◽  
Chronic Liver ◽  
Mineral Density

scholarly journals Optimal Skeletal Muscle Mass Index Cut-Off Values for Presarcopenia Evaluated by Computed Tomography against Dual-Energy X-ray Absorptiometry in Patients with Chronic Liver Disease

2021 ◽  
Vol 10 (7) ◽  
pp. 1419
Author(s):  
Kazuki Ohashi ◽  
Toru Ishikawa ◽  
Asami Hoshii ◽  
Tamaki Hokari ◽  
Hirohito Noguchi ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Skeletal Muscle ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Dual Energy ◽  
Chronic Liver ◽  
X Ray ◽  
Skeletal Muscle Mass Index

Although dual-energy X-ray absorptiometry (DXA) and body impedance analysis are commonly used to measure skeletal muscle mass (SMM), a computed tomography (CT) scan is preferred in clinical practice. We aimed to propose the cut-off values of skeletal muscle mass index (SMI) calculated using CT scans, using DXA as the reference method. We retrospectively assessed 589 patients with chronic liver disease. The SMI was assessed using appendicular SMM by DXA and total muscle area at the level of the third lumbar vertebra (L3) calculated by CT. The cut-off value was determined with reference to the Asian Working Group for Sarcopenia criteria. DXA identified 251 (42.6%) patients as having presarcopenia. In men, the cut-off value of SMI for presarcopenia was determined to be 45.471 cm2/m2, with an area under the curve (AUC) of 0.863 (95% confidence interval (CI): 0.823 to 0.903), and in women, this value was determined to be 35.170 cm2/m2, with an AUC of 0.846 (95% CI: 0.800 to 0.892). Cohen’s kappa coefficient was 0.575 (95% CI: 0.485–0.665) in men and 0.539 (95% CI: 0.438–0.639) in women.

scholarly journals Relationship between Muscle Mass and Non-Alcoholic Fatty Liver Disease

Biology ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 122
Author(s):  
Jun-Hyuk Lee ◽  
Hye-Sun Lee ◽  
Byoung-Kwon Lee ◽  
Yu-Jin Kwon ◽  
Ji-Won Lee
Keyword(s):  
Skeletal Muscle ◽  
Risk Factor ◽  
Liver Disease ◽  
Fatty Liver ◽  
Muscle Mass ◽  
Fatty Liver Disease ◽  
Skeletal Muscle Mass ◽  
Liver Fat ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Although sarcopenia is known to be a risk factor for non-alcoholic fatty liver disease (NAFLD), whether NAFLD is a risk factor for the development of sarcopenia is not clear. We investigated relationships between NAFLD and low skeletal muscle mass index (LSMI) using three different datasets. Participants were classified into LSMI and normal groups. LSMI was defined as a body mass index (BMI)-adjusted appendicular skeletal muscle mass <0.789 in men and <0.512 in women or as the sex-specific lowest quintile of BMI-adjusted total skeletal muscle mass. NAFLD was determined according to NAFLD liver fat score or abdominal ultrasonography. The NAFLD groups showed a higher hazard ratios (HRs) with 95% confidence intervals (CIs) for LSMI than the normal groups (HRs = 1.21, 95% CIs = 1.05–1.40). The LSMI groups also showed a higher HRs with 95% CIs for NAFLD than normal groups (HRs = 1.56, 95% CIs = 1.38–1.78). Participants with NAFLD had consistently less skeletal muscle mass over 12 years of follow-up. In conclusion, LSMI and NAFLD showed a relationship. Maintaining muscle mass should be emphasized in the management of NAFLD.

scholarly journals Imaging Software-Based Sarcopenia Assessment in Gastroenterology: Evolution and Clinical Meaning

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Giovanni Marasco ◽  
Sinan Sadalla ◽  
Giulio Vara ◽  
Rita Golfieri ◽  
Davide Festi ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Liver Disease ◽  
Liver Failure ◽  
Chronic Liver Disease ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Failure ◽  
Cross Sectional ◽  
Cross Sectional Imaging ◽  
Sectional Imaging

Sarcopenia is gaining attention as a negative prognostic factor in different fields of medicine, including chronic liver failure. However, the assessment of sarcopenia in patients with liver diseases is often neglected due to unawareness of reliable tools and methods and thus is limited to research studies. Cross-sectional imaging is a diffuse diagnostic tool and is commonly performed in patients with chronic liver failure. The last advancements in radiology image analysis using dedicated software allow an easy and standardized method to assess skeletal muscle volume. Several measures can be obtained from cross-sectional imaging analysis to evaluate sarcopenia in patients affected by chronic liver disease. We aimed to review the recent advances in imaging-based sarcopenia assessment, in particular in patients with chronic liver diseases. As a result, we found that the skeletal muscle index (SMI) seems to be a reliable method to assess sarcopenia in cirrhotic patients. Even if further studies are needed to validate proper cut-offs for each clinical endpoint, physicians are invited to consider the assessment of sarcopenia in the work-up of patients with chronic liver disease.

scholarly journals Effects of in-hospital exercise on liver function, physical ability, and muscle mass during treatment of hepatoma in patients with chronic liver disease

2016 ◽  
Vol 47 (3) ◽  
pp. E22-E34 ◽  
Author(s):  
Shunji Koya ◽  
Takumi Kawaguchi ◽  
Ryuki Hashida ◽  
Emiko Goto ◽  
Hiroo Matsuse ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Function ◽  
Chronic Liver Disease ◽  
Muscle Mass ◽  
Chronic Liver ◽  
Physical Ability

scholarly journals Nonalcoholic Fatty Liver Disease Is Associated With Low Skeletal Muscle Mass in Overweight/Obese Youths

2020 ◽  
Vol 8 ◽  
Author(s):  
Lucia Pacifico ◽  
Francesco Massimo Perla ◽  
Gianmarco Andreoli ◽  
Rosangela Grieco ◽  
Pasquale Pierimarchi ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Muscle Mass ◽  
Fatty Liver Disease ◽  
Skeletal Muscle Mass ◽  
Nonalcoholic Fatty Liver
Sign in / Sign up

Export Citation Format

Share Document